Navigation Links
A Better Acetabular Solution from StelKast ... Naturally
Date:4/15/2011

MCMURRAY, Pa., April 15, 2011 /PRNewswire/ -- StelKast is proud to announce the recent FDA 510(k) clearance of their new EXp™ Acetabular Liners. EXp™, a blend of antioxidant and highly cross-linked polyethylene technology was developed with the consulting support of Steven Kurtz, Ph.D. and Exponent, Inc. (Philadelphia, PA). StelKast has also received 510(k) clearance for large diameter cobalt-chrome femoral heads and Biolox® delta femoral heads.

(Logo:  http://photos.prnewswire.com/prnh/20110415/LA83876LOGO)

Mr. Peter Stephans, Chairman & CEO, said in a statement, "EXp™ polyethylene technology represents an optimal blend of UHMWPE, the antioxidant vitamin E (alpha-tocopherol), and cross-linking for long-term oxidative stability, preservation of mechanical properties and performance. Unlike other highly cross-linked materials, EXp™ polyethylene requires no thermal processing or infusion of antioxidants to stabilize the material. The combination of EXp™ Acetabular Liners and large diameter heads promotes joint stability.

"StelKast is excited to be the first US orthopedic company to provide a highly crosslinked vitamin E blended acetabular system offering superior oxidation resistance. The introduction of EXp™ polyethylene is just another example of StelKast's commitment to place emerging technology and high quality implants in surgeon's hands through cost effective solutions."

Full commercial launch of the EXp™ Acetabular System is planned for July 2011. For inquiries, please contact your local StelKast representative or Customer Service at 888-273-1583.

StelKast specializes in the design, manufacture, and distribution of hip and knee implant systems. The Company's mission is to provide high-quality, cost effective solutions to meet the challenges of the orthopedic community through clinically proven design concepts and innovative technology. For more information about StelKast, please visit the company website at www.stelkast.com.

Source: StelKast Inc.
Ph 888.273.1583
Fax 724.941.5987
200 Hidden Valley Road
McMurray, PA 15317 USA
www.stelkast.com


'/>"/>
SOURCE StelKast Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Hypertension: Journal of the American Heart Association Rapid Access Reports: Hispanics Hypertension Better Controlled With Equal Access to Care
2. First High-Res 3-D Structures of Mammalian HSP90 Protein Solved, Key to Better Targets for AIDS, Sepsis, Cancer Drugs
3. Organ Donor Shortage Remains Obstacle for Would-Be Transplant Patients Despite Better Medicine
4. Research Presented at ISHLT Shows Promise of Addressing Critical Organ Shortage and Better Organ Preservation
5. Study Shows Once-Yearly Reclast Better than Risedronate at Increasing Bone Mass in Patients With Osteoporosis Caused by Glucocorticoids
6. Phreesia Announces Clinical Initiative to Better Manage Symptoms of Parkinsons Disease
7. In Blood Vessel Stents, Innovative Materials Allow Better Control, Delivery of Gene Therapy
8. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
9. Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM)
10. Halozyme Therapeutics Announces Phase I Clinical Trial Results Demonstrating that the Combination of Recombinant Human Hyaluronidase (rHuPH20) With Humulin R(R) and with Humalog(R) Yields Faster, More Physiologic Insulin Kinetics and Better Predictability
11. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2017)... 2017 Oramed Pharmaceuticals Inc. (NASDAQ: ... focused on the development of oral drug delivery systems, ... (FDA) has agreed to schedule an End-of-Phase II meeting ... of its oral insulin capsule ORMD-0801 in the treatment ... primary and secondary endpoints by indicating a statistically significant ...
(Date:7/10/2017)... PARK, N.C. , July 10, 2017 ... $5m Convertible Note to support the development of CRISPR-Cas3 ... Tencent Holdings Limited, a leading Chinese Internet services provider, ... funding will advance multiple infectious disease product programs targeting ... Founded by Dr. Rodolphe ...
(Date:7/5/2017)... Wash. , July 5, 2017   BioLife ... leading developer, manufacturer and marketer of proprietary clinical grade ... cryopreservation freeze media ("BioLife"), today announced that it ... its debt holder and largest shareholder, to modify its ... Pursuant to the modification, WAVI agreed to exchange ...
Breaking Medicine Technology:
(Date:7/20/2017)... Plainview, NY, July 20, 2017 (PRWEB) , ... ... ... Nastel Technologies, a global provider of enterprise-grade IT operations analytics and ... delivery arm of one of world’s largest healthcare services providers. , According ...
(Date:7/20/2017)... , ... July 20, 2017 , ... ... telemedicine platform, in which their iMedSecure™ comes included with each system installation. ... live images to remote participants for real-time collaboration and immediate decision-making requirements. ...
(Date:7/20/2017)... ... July 20, 2017 , ... Vixiar Medical, Inc. , ... systems for monitoring cardiopulmonary diseases, announced today that it has raised seed round ... submissions and fund final engineering and initial production of the Company’s first product, ...
(Date:7/20/2017)... ... July 20, 2017 , ... The Dermatology Clinic announced today the addition of ... in Biology from LSU, graduating summa cum laude. He attended Emory University School of ... in St. Louis, Dr. Dunbar moved to New York to complete an AGCME-accredited Mohs ...
(Date:7/20/2017)... ... July 20, 2017 , ... ... Business Architecture Body of Knowledge (BIZBOK® Guide )v 6.0 is now available for ... this effort through Guild collaborative teams. , Non-members may download the Part ...
Breaking Medicine News(10 mins):